Correlation Between CEUS Identification of Nodular HPD on CE-MRI and Hepatic Malignant Lesions

Condition(s) studied

Study summary

Hepatic malignant tumors are a category of diseases with high incidence and mortality rates worldwide, including various types such as primary hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (ICC), and liver metastases. With the advancement of imaging technology, the number of hepatic perfusion disorders (HPD) detected in high-risk population screening and follow-up has gradually increased. However, the imaging manifestations of these HPD are highly heterogeneous, and the imaging features of some benign lesions (such as post-treatment inflammatory reactions, arterioportal shunts, hyperplastic nodules, focal fat deposition or fibrotic nodules) overlap with those of malignant lesions, posing a challenge to accurate diagnosis. Therefore, how to improve the ability to distinguish the benign and malignant nature of HPD based on multimodal imaging technology and optimize the follow-up management of high-risk populations has significant clinical value.

Eligibility

Primary outcome measure(s)

• Accuracy — 2 years
  The diagnostic model correctly distinguish between hepatic malignant lesions and benign nodular hepatic perfusion disorders.
• Correlation — 2 years
  Correlation between nodular HPD and hepatic malignant lesions
• False negative rate — 2 years
  The probability of misdiagnosing malignant liver lesions as benign nodular HPD by CE-MRI

Trial sites (1)

More Second Affiliated Hospital, Zhejiang University, School of Medicine trials in China